RARE PHOTOS: Centessa - The Real Truth

Shares of Centessa Pharmaceuticals plc skyrocketed more than 44% Tuesday after the clinical-stage biotech announced it would be acquired by pharmaceutical giant Eli Lilly and Co. in a deal valued at up to $7.8 billion, giving Lilly a promising pipeline of experimental treatments for sleep-wake disorders.

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…